Biosimilars and the Regulation of Oncological Preparations in Germany Background
As an advanced market for biosimilars in present, Europe will become even more important expecting patent expiries of top biologicals until 2020. In future, biosimilars will be increasingly used in the form of oncological preparations produced by specialist pharmacies. In Germany, purchase-and pricing regulations on these markets differ from markets of pharmaceuticals directly sold in pharmacies. From 2017, there is a new regulation for markets of pharmaceutical preparations. The aim of this study is the critical assessment of the regulation on these markets especially with regard to market access of biosimilars. 
Methods
Walendzik A, Altin S, May U, Bauer C, Ziebe A, Wasem J General regulations for preparation markets lead to a key role of specialist pharmacies or their purchasing organizations in pricing, as they buy the ingredients independently from pricing regulations on the general pharmaceutical markets. Their market power in biological markets is only reduced by the non-substituability of biologicals and biosimilars by pharmacists.
Results

Discussion
Before 2018, pricing of pharmaceutical preparations could be done in two ways:
• According to price regulations by selective contracting between the Federal Association of Statutory Health Funds and the German Association of Pharmacists in the so-called "Hilfstaxe". • Basing on selective contracting of singular health funds with pharmacies.
Instruments of the "Hilfstaxe" were agreed percentual rebates on the second lowest purchase price of the used pharmaceutical ingredient and fixed surcharges for preparations activities.
The Pharmaceutical Care Strengthening Act 2017 determined substantial changes to pricing regulations for pharmaceutical preparations:
• Ban of former selective contracting of individual health funds with pharmacies • Duty of collectively contracting a new "Hilfstaxe" • Duty of pharmacists, their federations and pharmaceutical companies to disclose the purchase prices of pharmacies • Introduction of the possibility for health funds on the regional level to collectively contract with pharmaceutical companies about purchase prices for preparation ingredients Figure 1 : Regulation elements of the market for oncological preparations Fig. 1 shows the present regulation instruments adressing the market of oncological preparations. Whether the instruments of regional collective contracts on ingredients are interesting for health funds, depends on the pricing regulations of the Hilfstaxe. The only measures directly influencing the prescribing oncologists are the regional regulations concerning efficiency evaluation, e.g.in the form of biosimilar prescription quotas. In January, 2018 the new "Hilfstaxe" was installed by arbitration decision. Main changes in comparison to the former version were:
• Much higher rebates on prices of generics (up to 83,7 %) • Lower rebates on prices of biological products in comparison to generics, but in the case of Rituximab a lower discount on the original (4,2%) than on the biosimilar (7,5%) • Introduction of a small discount on prices of patented pharmaceuticals (1,6%)
Using the new transparency rules, the "Hilfstaxe" seems to be able to socialize a higher part of the discounts negotiated by the specialist pharmacists and their organizations. Nevertheless, the application of a lower rebate in case of a biological in comparison to its biosimilar leads to advantages on the market for the supplier of the biological. Up to now the incentive situation is limited by the fact, that the decision of the prescribing oncologist can not be modified by the specialist pharmacy. If in the future the legislator may allow the substitution of biologicals and biosimilars by pharmacists, at the latest it seems to be necessary to reconsider the regulations of the "Hilfstaxe".
On a more general level it could be discussed whether an alternative measure could be the application of the German general regulation of pharmaceutical markets to markets for pharmaceutical regulations as well.
